Medicina
Department
Complexo Hospitalario Universitario de Ferrol
Ferrol, EspañaPublications in collaboration with researchers from Complexo Hospitalario Universitario de Ferrol (15)
2022
-
Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry
ESC Heart Failure, Vol. 9, Núm. 4, pp. 2189-2198
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
2020
-
Deprescribing of non-antiretroviral therapy in HIV-infected patients
European Journal of Clinical Pharmacology, Vol. 76, Núm. 3, pp. 305-318
-
Fracture risk assessment in the general population in Spain by FRAX® algorithm. EPISER2016 study
Medicina Clinica, Vol. 154, Núm. 5, pp. 163-170
2019
-
Diverse large HIV-1 non-subtype B clusters are spreading among men who have sex with men in Spain
Frontiers in Microbiology, Vol. 10, Núm. APR
-
Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 195-202
-
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients
Annals of Hematology, Vol. 98, Núm. 2, pp. 321-330
2018
-
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: Results of the neurocognitive substudy of the SALT randomized clinical trial
Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 9, pp. 2444-2451
2017
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2015
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
2012
-
Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens
Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 6, pp. 1462-1469
2009
-
HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with virological failure to nucleoside drug combinations
Journal of Antimicrobial Chemotherapy, Vol. 64, Núm. 2, pp. 251-258
2008
-
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092
2007
-
Characteristics and outcome of acute myocardial infarction in young patients: The PRIAMHO II study
Cardiology, Vol. 107, Núm. 4, pp. 217-225
2002
-
Estudio nutricional en pacientes geriátricos (mayores de 65 años) con nutrición enteral ambulatoria, correlación entre patología de base, aporte nutricional y tratamiento farmacológico
Nutricion Hospitalaria, Vol. 17, Núm. 3, pp. 159-167